TELA Bio, Inc.

TELAHealthcare · Medical - DevicesVisit siteCIK 0001561921

Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.): $48.1M
Price: $1.06
% Change (Daily % change from the live per-ticker quote feed.): -2.29%
Volume: 161.7K

About

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Quick stats

Shares outstanding45.1M

Computed float37.2M

Float / shares82.4%

Cash runway (months)6.5

Key info

SectorHealthcare

IndustryMedical - Devices

CIK0001561921

Websitehttps://www.telabio.com

AI Summary

AI-generated

1/16

3d ago

standardbullishfda approval

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement.

Liora is the first implant fully developed in the company's ISO 8 certified cleanroom in Malvern, PA, and expands its soft tissue reconstruction portfolio.

Additional launch details are expected on the Q3 earnings call in early November.